NewLimit raises $435.0M Series C (United States, Jun 2026)
Reach the investors backing rounds like this
Backed by Founders Fund, Thrive Capital +1 more · verified emails and LinkedIn on Datapile
Coinbase CEO’s Longevity Startup NewLimit Raises $435 Million - CoinCentral
NewLimit is a longevity biotech startup focused on reversing cellular aging through epigenetic reprogramming. The company aims to develop drugs that reset gene expression in aged cells, with plans to start human clinical trials in 2027 targeting alcohol-related liver disease. This funding round has significantly increased its valuation, reflecting strong investor confidence in its innovative approach.
Coinbase CEO’s Longevity Startup NewLimit Raises $435 Million CoinCentral
20,207 investors back startups in United States
You just read who funded NewLimit. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 5 investor contact unlocks a month, no card required.